| 2.095 0.215 (11.44%) | 06-17 13:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.44 | 1-year : | 4.53 |
| Resists | First : | 2.95 | Second : | 3.88 |
| Pivot price | 2.12  |
|||
| Supports | First : | 1.45 | Second : | 1.2 |
| MAs | MA(5) : | 1.92 |
MA(20) : | 2.1 |
| MA(100) : | 1.74 |
MA(250) : | 2.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 16.3 |
D(3) : | 15.9 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 4.5 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AIMD ] has closed above bottom band by 47.8%. Bollinger Bands are 38.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.94 - 1.95 | 1.95 - 1.96 |
| Low: | 1.8 - 1.82 | 1.82 - 1.83 |
| Close: | 1.86 - 1.88 | 1.88 - 1.9 |
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Wed, 17 Jun 2026
Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program - newswire.com
Wed, 17 Jun 2026
Ainos Inc (AIMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tue, 09 Jun 2026
Ainos (AIMD) director reports 3,500-share open-market purchase through spouse - Stock Titan
Fri, 05 Jun 2026
VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations - News-Press NOW
Fri, 05 Jun 2026
Ainos (AIMD) director buys 2,000 shares in indirect open-market trade - Stock Titan
Mon, 01 Jun 2026
Hospital tests ‘Smell AI’ to flag ER overcrowding and infection risks - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 7.36e+006 (%) |
| Held by Institutions | 2.38e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 14340 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.83 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 418 % |
| Return on Equity (ttm) | 414.2 % |
| Qtrly Rev. Growth | -148.3 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | -0.01 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | -8.33e+006 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0.9 |
| Price to Book value | -0.75 |
| Price to Sales | -38230.7 |
| Price to Cash Flow | 0 |
| Dividend | 91820 |
| Forward Dividend | 21700 |
| Dividend Yield | 4372380% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|